Co-infection with SARS-CoV-2 and other respiratory pathogens is more common than previously expected, according to a Stanford study.
Stanford researchers are working on a test to identify early-stage lung cancer by detecting tumor-specific mutations in bits of DNA in the bloodstream.
Stanford researchers study stem-cell-derived human heart muscle cells on the International Space Station to learn effects of microgravity.
Mammalian cells use a label to distinguish self from non-self circular RNA molecules. Foreign molecules can trigger anti-cancer immune responses.
The Myc oncogene helps cancer cells stockpile the fat, or lipids, necessary for rapid growth. Blocking this activity causes human tumors in mice to shrink.
Stanford researcher Eleni Linos turned to social media to see if it was a more effective way to spread information about skin cancer and tanning to youth.
The bacteria in our gut make tiny, previously unidentified proteins that could shed light on human health and advance drug development.
Frustrated by the poor options for their patients, two neurosurgery residents left to study basic science at Stanford, developing a drug for brain tumors.
Stanford clinicians take their cue from sports and election predictions to calculate an "in-game probability" of success when treating cancer patients.
Many metastatic colorectal cancers appear "born to be bad," spreading to other organs before any diagnosis has been made, say Stanford researchers.
A state-of-the-field review of stem cell research by Stanford's Helen Blau reveals their promise & exposes problems in the path to clinical applications.
E-cigarette flavorings are harmful to blood vessel cells even in the absence of nicotine. The flavors of cinnamon and menthol are particularly dangerous.
Stanford researchers are using lab-grown heart cells to investigate how Chagas disease, which is spread by "kissing bugs," affects heart health.
The prevalence of genetic testing in the United States falls short of the recommended guidelines for women with ovarian cancer, new research indicates.
Molecular data identifies breast cancer subgroups likely to recur decades after successful treatment, predicts probable timing and location of metastases.
An antibody against the "don't eat me" signal on cancer cells appears safe and well-tolerated by patients with advanced cancers. A phase 2 trial is planned.